Related Experiment Video
Updated: Aug 1, 2026
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
HMG-CoA Reductase Inhibitors for Traumatic Brain Injury
Kalman Katlowitz1, Shankar Gopinath2, Jovany Cruz Navarro2
1Department of Neurosurgery, Baylor College of Medicine, Houston, TX, 77030, USA. Kalman.katlowitz@bcm.edu.
Insights
Statins show promise for managing traumatic brain injuries (TBIs) by reducing secondary neurological damage. Further research is needed to establish optimal treatment protocols for these promising TBI therapeutics.
Area of Science:
- Neuroscience
- Pharmacology
- Trauma Care
Background:
- Traumatic brain injuries (TBIs) cause significant morbidity and mortality.
- Secondary injury cascades exacerbate initial TBI damage.
- Statins, known for cardiovascular benefits, possess pleiotropic effects including anti-inflammatory and angiogenic properties.
Purpose of the Study:
- To review the potential of statins in managing TBI.
- To evaluate evidence from preclinical and clinical studies on statin efficacy in TBI.
Main Methods:
- Review of preclinical studies, retrospective analyses, and existing randomized clinical trials.
- Analysis of statins' mechanisms of action beyond cholesterol inhibition.
Main Results:
- Statins demonstrate potential benefits in TBI management across various study types.
- Evidence suggests statins may mitigate secondary neurological injury.
- No large-scale randomized clinical trials have been completed to date.
Conclusions:
- Statins represent a promising therapeutic option for TBI due to their potential benefits and favorable side effect profile.
- Further rigorous clinical investigation is required to define optimal statin regimens and fully elucidate their therapeutic potential in TBI.
Abstract:
Traumatic brain injuries (TBIs) are associated with high morbidity and mortality due to both the original insult as well as the destructive biological response that follows. Medical management aims to slow or even halt secondary neurological injury while simultaneously laying the groundwork for recovery. Statins are one class of medications that is showing increased promise in the management of TBI. Used extensively in cardiovascular disease, these drugs were originally developed as competitive inhibitors within the cholesterol production pipeline. They are now used in diverse disease states due to their pleiotropic effects on other biological processes such as inflammation and angiogenesis. Preclinical studies, retrospective reviews, and randomized clinical trials have shown a variety of benefits in the management of TBI, but to date, no large-scale randomized clinical trial has been performed. Despite this limitation, statins' early promise and well-tolerated side effect profile make them a promising new tool in the management of TBIs. More bench and clinical studies are needed to delineate proper treatment regimens as well as understand their true potential.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:28Traumatic Brain Injury l: Introduction